Articles from Lysoway Therapeutics, Inc.

Lysoway Therapeutics today announced that the first participant has been successfully dosed on May 5, 2026 in the Company’s Phase I clinical trial of LW-1017, a potent, selective, and highly brain-penetrant small-molecule TRPML1 agonist being developed for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease.

Lysoway Therapeutics, Inc., a biotechnology company advancing structure-guided small-molecule modulators of lysosomal ion channels to treat age-related neurodegeneration, today announced that its lead TRPML1 agonist, LW-1017, is Phase I ready. A first-in-human (FIH) study is planned in Australia, with first patient first dose (FPFD) targeted for May 2026. The Company also announced the formal nomination of a development candidate for its TMEM175 agonist program, reflecting the reproducibility of its discovery platform.

Lysoway Therapeutics, Inc., a biopharmaceutical company developing small molecule modulators of lysosomal ion channels, today announced that it has received a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF). Support comes from MJFF’s Parkinson’s Disease Therapeutics Pipeline Program, which focuses on candidates with strong potential to slow or halt disease progression or alleviate burdensome symptoms for those living with Parkinson’s disease. Lysoway Therapeutics funding of $2.93 million will support the preclinical and translational development of Lysoway’s novel, highly brain-penetrant small molecule TRPML1 agonist.